
    
      This is a phase 1, first-in-human study to evaluate the safety and tolerability of AMG 119,
      an investigational, Chimeric Antigen Receptor T cell therapy targeting delta-like protein 3
      (DLL3) in subjects with relapsed/refractory small cell lung cancer who progressed after at
      least 1 platinum based chemotherapy regimen.
    
  